Agreed, price is too low,
From goog.
AI Overview
A price-to-earnings (P/E) ratio of 9.54 for a pharmaceutical company is generally considered very low and potentially undervalued, especially compared to industry benchmarks.
+1
Here is a breakdown of what a 9.54 P/E means in the pharmaceutical sector:
Undervaluation Signal: A P/E under 15 for a mature company is often seen as "cheap" or a bargain, meaning investors are paying a low price for each dollar of profit.
We need more transparency from the DEA/FDA, about API, and need to clear up that crazy tariff problem,
Nobody knows where it’s going.
Bullish
Market Data 
Markets 
AI
